In the Phase III trial CheckMate‐067, nivolumab (a PD‐1 inhibitor) monotherapy or in combination with ipilimumab significantly improved the mPFS, mOS, and ORR compared with ipilimumab in patients with metastatic melanoma [402, 403, 404]. Here, PDCD1 is linked to metastatic melanoma.